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http://dx.doi.org/10.1016/j.ccr.2014.02.010SUMMARYSomatic mutations in DNMT3A, which encodes a de novo DNA methyltransferase, are found in 30% of
normal karyotype acute myeloid leukemia (AML) cases. Most mutations are heterozygous and alter R882
within the catalytic domain (most commonly R882H), suggesting the possibility of dominant-negative conse-
quences. The methyltransferase activity of R882H DNMT3A is reduced by 80% compared with the WT
enzyme. In vitro mixing of WT and R882H DNMT3A does not affect the WT activity, but coexpression of
the two proteins in cells profoundly inhibits the WT enzyme by disrupting its ability to homotetramerize.
AML cells with the R882H mutation have severely reduced de novo methyltransferase activity and focal
hypomethylation at specific CpGs throughout AML cell genomes.INTRODUCTION
Acute myeloid leukemia (AML) is a malignancy of hematopoietic
stem/progenitor cells (HSPCs) with considerable clonal and ge-
netic heterogeneity (Welch et al., 2012; Ding et al., 2012; Ley
et al., 2013). Some AML patients have recurrent translocations
that cause gene fusions (i.e., PML-RARA, RUNX1-RUNX1T1,
CBFB-MYH11, MLL fusions, etc.), which are associated with
canonical alterations in gene expression and DNA methylation
patterns (Figueroa et al., 2010; Ley et al., 2013). Recent studies
have revealed that patients with normal karyotype (NK) AML
exhibit a high frequency of mutations in genes involved with
DNA methylation, including DNMT3A (30%–35%), IDH1 orSignificance
Mutations in epigeneticmodifier genes have been identified in s
KDM6A,ASXL1,MLL, and others in AML. Themechanisms byw
are not entirely clear. Here we demonstrate that the common
negative activity against WT DNMT3A, disrupting the ability of
quence, AML samples with DNMT3A mutations at R882 ar
genomes. This suggests that two classes of DNMT3A muta
de novo DNA methyltransferase activity, whereas non-R882 m
mechanisms.
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alterations in DNAmethylationmay play an important role in early
disease pathogenesis for this group of AML patients (Delhom-
meau et al., 2009;Mardis et al., 2009; Ley et al., 2010, 2013;Mar-
cucci et al., 2012).
DNMT3A mutations are generally present in the founding
clones of AML samples, suggesting that they may initiate leuke-
mia (Ding et al., 2012; Ley et al., 2013; Miller et al., 2013).
However, the mechanisms by which they contribute to leukemo-
genesis are not yet clear. Previous studies of Dnmt3a function
using mouse models have shown that haploinsufficiency for
Dnmt3a results in no obvious alterations in hematopoiesis,
whereas HSPCs completely lacking DNMT3A protein exhibiteveral cancers, includingDNMT3A, IDH1, IDH2, TET2, EZH2,
hichmutations inDNMT3A contribute to AML pathogenesis
R882H mutation creates an altered protein with dominant-
the WT enzyme to form active homotetramers. As a conse-
e associated with focal hypomethylation throughout their
tions exist: R882 mutations cause a striking reduction of
utations may contribute to AML pathogenesis via different
AC
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Figure 1. Expression of DNA Methyltransferase Genes in NK-AML
Samples
(A) FPKM expression of DNA methyltransferase family genes in NK-AML by
RNA-seq (n = 80).
(B) Variant allele frequency (%) of R882 mutant DNMT3A in NK-AML tumor
DNA and RNA. Each set of connected points corresponds to a single patient
(n = 23).
(C) TripleTOF mass spectrometry identification of WT and R882H DNMT3A in
primary NK-AML cell lysates. The x axis reflects peptide retention time (min),
which distinguishes between the two peptides that define WT versus R882H
DNMT3A proteins. The y axis reflects signal intensity for heavy peptides
([13C6][
15N4]-labeled internal standard synthetic peptides corresponding toWT
or R882HDNMT3A; negative on axis) or light peptides (endogenous, nativeWT
and R882H DNMT3A; positive on axis), based on specific y series ion transi-
tions (curves y3-y12). All endogenous DNMT3A signals exhibiting mean
retention times (dashed vertical lines) within the 95% confidence interval of the
heavy internal standard mean retention time (vertical gray shading and solid
vertical lines) are shown.
See also Figure S1.
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Dominant-Negative R882H DNMT3A in AMLincreased self-renewal and decreased differentiation upon serial
transplantation (Tadokoro et al., 2007; Challen et al., 2012). How-
ever, more than half of DNMT3A mutations in AML samples are
heterozygousmissense alterations within the catalytic domain of
the enzyme at residue R882, most commonly resulting in an argi-
nine-to-histidine change (Ley et al., 2010; Shen et al., 2011; Thol
et al., 2011; Yan et al., 2011; Marcucci et al., 2012; Renneville
et al., 2012; Ribeiro et al., 2012). The high frequency of mutations
at this specific site raises the possibility that this amino acidchange creates a gain-of-function activity and/or produces a
protein with a dominant-negative effect on the residual wild-
type (WT) protein.
Previous studies of R882 mutations in recombinant DNMT3A
produced in several systems have demonstrated that these
mutations confer reduced de novo methyltransferase activity
in vitro. Prior to the discovery of this mutation in AML, the homol-
ogous R878 residue in murine DNMT3A wasmutated in a screen
of the C-terminal catalytic methyltransferase domain of DNMT3A
purified from E. coli (Gowher et al., 2006); this mutation reduced
its methyltransferase activity and also its DNA and S-adenosyl-
methionine (SAM, or AdoMet) binding capacity. Full-length hu-
man DNMT3A with the R882H mutation purified from Sf9 insect
cells confirmed that this mutation has reduced activity in an
in vitro methylation assay (Yamashita et al., 2010). Additional
studies of recombinant DNMT3A have examined its interactions
with DNMT3L, a related (but catalytically inactive) protein that
contributes to the regulation of DNMT3A oligomerization and en-
hances its methyltransferase activity (Jia et al., 2007; Holz-
Schietinger and Reich, 2010). Complexes of full-length DNMT3A
and DNMT3L copurified from E. coli demonstrated the hypomor-
phic activity of R882H DNMT3A relative to WT DNMT3A (Yan
et al., 2011). More detailed analysis of the properties of the cat-
alytic domain of DNMT3A (also purified from E. coli) revealed that
the R882H mutation disrupted its ability to form tetramers (Holz-
Schietinger et al., 2012). This mutation reduced the processive
methylation of consecutive CpG dinucleotides in vitro, but this
effect was significantly rescued by the addition of DNMT3L.
Importantly, the dominant-negative potential of the R882 muta-
tions was highlighted by a recent study where murine DNMT3A
R878H (equivalent to R882H in human DNMT3A) was shown to
inhibit de novo DNA methylation by WT DNMT3A in murine ES
cells (Kim et al., 2013).
In this study, we explored potential mechanisms that
could explain how a heterozygous, hypomorphic R882H allele
could affect de novo methylation beyond causing simple
haploinsufficiency.
RESULTS
Characterizing the DNA Methylation Potential of
NK-AML Cells
To explore the functional consequences of the R882H DNMT3A
mutation in AML, we first characterized patterns of expression of
the DNAmethyltransferases in a set of 80 primary NK-AML sam-
ples from the TCGA AML cohort (Ley et al., 2013). RNA
sequencing (RNA-seq) data confirmed that DNMT1, the mainte-
nance DNA methyltransferase, was the most highly expressed
DNMT gene (mean fragments per kilobase of transcript per
million mapped reads [FPKM] = 15.91, SD = 5.82; comparison
of DNMT1 relative to DNMT3A, p = 0.004; Figure 1A). DNMT3A
is known to be dynamically regulated during normal and malig-
nant hematopoiesis (Mizuno et al., 2001; Challen et al., 2012);
we observed substantial DNMT3A expression in all NK-AML
samples (mean FPKM = 12.97, SD = 6.95, Figure 1A). Further,
DNMT3A was expressed on average 2.3-fold higher than
DNMT3B (mean FPKM = 4.27, SD = 3.10). Importantly, 95%
(76/80) of NK-AML patients predominantly expressed inactive
splice variants of DNMT3B, irrespective of FAB or DNMT3ACancer Cell 25, 442–454, April 14, 2014 ª2014 Elsevier Inc. 443
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Dominant-Negative R882H DNMT3A in AMLmutation status (median ratio of inactive to active DNMT3B tran-
scripts was 3:1; Figure S1 available online). DNMT3L expression
was not detected in the vast majority of NK-AML cases, although
very minimal expression was present in 13 cases (mean FPKM =
0.04, SD = 0.16, Figure 1A).
The variant allele frequency (VAF) of somatic mutations at
R882 inDNMT3Awas approximately 50% inmost samples, indi-
cating that R882 mutations are almost always heterozygous and
are present in nearly all cells in most AML samples (i.e., they are
nearly always in founding clones); based on the similar VAFs of
the R882 mutations in RNA-seq data, we conclude that these
mutations do not alter the expression or stability of DNMT3A
mRNA (Figure 1B).
The existence of R882H DNMT3A protein in AML cells has not
yet been reported, and it is possible that the R882H mutation
produces an unstable protein that causes functional haploinsuf-
ficiency for DNMT3A at the protein level. We therefore developed
a selected reaction monitoring mass spectrometric assay to
specifically quantify the relative abundance of WT and R882H
DNMT3A proteins in NK-AML whole-cell lysates (one was WT/
WT for DNMT3A [TCGA#3008], and the other had a heterozy-
gous R882H DNMT3A mutation [TCGA#2896] with a VAF of
43.1%).We exploited the alteration of a tryptic digest site caused
by the R882H mutation (WT peptide = VFGFPVHYTDVSNMSR;
R882H peptide = VFGFPVHYTDVSNMSHLAR) and used heavy
([13C6][
15N4]-labeled) synthetic peptides containing these se-
quences as internal standards to identify and quantify endoge-
nous WT and R882H DNMT3A (Figure 1C). We demonstrated
that the WT- and R882H-specific peptides from the endogenous
proteins coeluted with isotopically labeled synthetic peptides of
the same amino acid sequence; we detected only the WT
DNMT3A peptide in the DNMT3AWT/WT lysate and found both
the WT and R882H DNMT3A peptides in the mutant lysate.
Positive identification was achieved by matching the ion chro-
matograms from the respective peptide fragmentation spectra
(isotopically labeled internal standard and peptides from endog-
enous proteins). We compared the relative signal intensities of
the endogenous WT and R882H peptides with the respective
heavy internal standards and found approximately equal
amounts of WT and R882H DNMT3A in the DNMT3AWT/R882H
sample (WT:R882 = 5.14:6.77 fmol). Together, these data sug-
gest that the de novo DNAmethylation potential of NK-AML cells
is almost exclusively provided by DNMT3A (because functional
DNMT3B and DNMT3L are generally not present in these cells).
Further, it suggests that the R882H mutation could produce a
maximal 50% reduction in the net de novo DNA methylation
potential in these cells—unless the mutant protein has a
dominant-negative activity.
Hypomethylation in NK-AML Genomes with DNMT3A
Mutations at R882
Although recent work in murine ES cells has shown that the
mouse equivalent of the R882H DNMT3A mutation can lead to
DNA hypomethylation in a dominant manner, it is important to
note that ES cells and AML cells possess substantially different
DNA methylation environments (Ziller et al., 2013)—notably,
Dnmt3l and active Dnmt3b are expressed in murine ES cells
(Chen et al., 2003), but not in NK-AML cells (Figure 1A). To define
the consequences of DNMT3Amutations on DNAmethylation in444 Cancer Cell 25, 442–454, April 14, 2014 ª2014 Elsevier Inc.primary human AML cells, we analyzed Illumina Infinium
HumanMethylation450 BeadChip (‘‘450K array’’) data from 85
cases of NK-AML in the TCGA AML cohort (Ley et al., 2013).
Although previous studies of global DNA methylation using
liquid chromatography-tandem mass spectrometry showed
thatDNMT3Amutations had no measureable effects on the total
(i.e., ‘‘bulk’’) 5-methylcytosine content in AML samples (Ley
et al., 2010), the 450K array platform allowed us to conduct a
high resolution analysis of DNA methylation in DNMT3A mutant
(‘‘R882’’ or ‘‘non-R882’’) and WT NK-AML samples at 464,198
CpGs found throughout the genome (see Supplemental Experi-
mental Procedures). We first compared the mean methylation
value across all array CpGs and found a small but statistically
significant difference between DNMT3A WT (n = 50) and R882
mutant samples (n = 20), with R882 mutant samples having a
lower mean methylation value (WT = 0.547 versus R882 =
0.511, p = 4.5 3 106; Figure 2A). In contrast, samples with
non-R882 mutations (n = 15) did not demonstrate a significant
difference inmeanmethylation relative toWT samples. However,
R882 and non-R882 mutant samples showed a statistically sig-
nificant difference in mean methylation that was similar to the
difference between R882 mutant and WT samples (non-R882 =
0.539 versus R882 = 0.511, p = 0.029). Levels of DNA methyl-
ation in NK-AML were not influenced by DNMT3B expression
or active/inactiveDNMT3B splice variant ratio (Figure S2A), high-
lighting the influence of DNMT3A on shaping the methylome of
NK-AML cells.
We next asked whether CpGs associated with particular
genomic features accounted for the hypomethylation phenotype
of samples with R882 mutations. To assess this, we compared
mean methylation levels of subsets of CpGs based on their
relationships to gene loci (promoter, gene body, 30 UTR, or inter-
genic) as well as CpG islands or ‘‘CGIs’’ (islands, shores,
shelves, or open sea) between WT, R882, and non-R882 mutant
NK-AMLs. All eight subsets demonstrated consistent hypome-
thylation in NK-AMLs with R882 mutations (Figure S2B), and,
similarly, hypomethylation was observed when examining each
chromosome independently (Figure S2C), demonstrating the
genome-wide nature of this phenotype.
To determine whether R882 mutations might have a more
striking effect on the methylation of a smaller subset of CpGs,
we identified the 5,000 most variably methylated CpGs accord-
ing to their methylation value SDs across all 85 NK-AML
samples. This set was comprised of genic (n = 3,466) versus
nongenic (n = 1,534), as well as CGI (n = 1,775) versus non-
CGI (n = 3,225) CpGs (Table S1). Hypomethylation was observed
in R882 mutant samples relative to those with WT DNMT3A
in 73.8% (3,690/5,000) of the CpGs (mean methylation value
difference between genotypes > 0.15). Additionally, samples
with R882 mutations exhibited lower mean methylation values
across these 5,000 CpGs than WT samples (WT = 0.539 versus
R882 = 0.306, p = 2.2 3 1016; Figures 2B and S2D), a much
greater difference than that detected across all CpGs on the
450K array. This effect was also observed when these 5,000
CpGs were organized by gene and CGI relationships (Fig-
ure S2E). Hierarchical clustering of all 85 NK-AML samples (as
well as 15 normal human control samples derived from purified
cells from human bone marrow samples: three CD34-enriched,
three promyelocyte-enriched, three monocyte-enriched, and
AC
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Figure 2. DNA Methylation Profiling of NK-
AML Samples Identifies a Focal Hypomethy-
lation Phenotype Associated with DNMT3A
R882 Mutations
(A) Aggregate density distribution of methylation
beta values for all CpGs for all patients based on
DNMT3A mutation status (black, DNMT3AWT/WT
[n = 50]; red, heterozygous DNMT3A mutation at
R882 [n = 20]; blue, non-R882 mutation in DNMT3A
[n = 15]). Mean methylation beta values are shown
for all CpGs for each patient based on the DNMT3A
mutation status. p values were calculated by t tests
corrected for multiple testing.
(B) Aggregate density distribution of methylation
beta values for the 5,000 most variably methylated
CpGs for all samples (categorized by DNMT3A
mutation status: black, DNMT3AWT/WT [n = 50]; red,
heterozygous DNMT3A mutation at R882 [n = 20];
blue, non-R882 mutation in DNMT3A [n = 15]).
Mean methylation beta values are shown for each
patient (categorized by DNMT3A mutation status)
for the 5,000 most variably methylated CpGs.
p values were calculated by t tests corrected for
multiple testing.
(C) Heatmap representation of unsupervised hier-
archical clustering of 85 NK-AML cases and 15
normal human bone marrow-derived samples
(enriched CD34+ cells, promyelocytes, neutrophils,
or monocytes), based on methylation beta values
for the 5,000 most variably methylated CpGs in the
sample set. The methylation beta value for each
CpG is represented by a color scale (red, less
methylated; yellow/white, more methylated). CpG
probes were ordered by similarity, as assessed by
hierarchical clustering analysis. The mutation sta-
tus of relevant, recurrently mutated genes in these
NK-AML samples is indicated above the heatmap.
See also Figure S2 and Table S1.
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Dominant-Negative R882H DNMT3A in AMLsix neutrophil-enriched samples) using these 5,000 CpGs re-
sulted in a distinct cluster of 14 cases with R882 mutations
(and 2 cases with non-R882 mutations) exhibiting very low levels
of DNA methylation at these 5,000 CpGs (Figure 2C). As ex-
pected, a separate cluster of cases with IDH1 or IDH2mutations
was detected, which was associated with higher levels of DNA
methylation at specific locations.
The most hypomethylated cluster of NK-AML cases was also
highly enriched for NPM1 mutations (p = 3.6 3 104). We there-
fore calculated mean methylation values across these 5,000
CpGs for all 85 NK-AML cases and compared the values for
DNMT3A WT and R882 mutant samples without NPM1 muta-
tions. All comparisons (the entire 5,000 CpG set, as well as the
genic/nongenic/CGI/non-CGI subsets of these 5,000 CpGs)
revealed significant hypomethylation in R882 mutant samples
relative to WT samples (Figure S2F), demonstrating that the
hypomethylation observed in the cases with R882 mutations is
independent of NPM1 mutations (although it is exaggerated
with NPM1 mutations).Cancer Cell 25, 442–To determine whether the hypomethyla-
tion associated with R882 mutations in
DNMT3A occurs consistently at specific
CpGs, we performed a supervised differ-ential methylation analysis to compare NK-AML genomes based
on DNMT3A mutation status (WT versus R882). Of the 464,198
CpGs included in our analysis, 29,660 (6.4% of assessed loci)
exhibited significant differential methylation between WT and
R882 mutant samples (false discovery rate [FDR]-adjusted
p value < 0.01 and mean methylation value difference between
genotypes > 0.15; Table S2), of which 29,658 (99.9%) were hy-
pomethylated in R882 samples (Figure 3A). We performed tar-
geted bisulfite sequencing and validated a specific, differentially
methylated CpG detected by the 450K array platform just
upstream from the p15/CDKN2B gene (Figure S3A). Importantly,
no CpGs were differentially methylated between WT and non-
R882 mutant samples (Figure 3B). Genome-wide DNA methyl-
ation studies have recently shown that most tissue-specific
differential DNA methylation occurs outside CGIs in the neigh-
boring 2 kb shores (Irizarry et al., 2009). Accordingly, we found
that the 29,658 hypomethylated CpGs specific to R882 mutant
samples were significantly enriched for CpG island shore loci
(p = 3.14 3 10223 by chi-square test; Figure S3B). Further, in454, April 14, 2014 ª2014 Elsevier Inc. 445
Figure 3. Differential Methylation in NK-AML Samples with R882 Mutant DNMT3A
(A) Scatter plot comparing meanmethylation beta values at individual CpGs across all NK-AML cases categorized by DNMT3Amutation status (WT versus R882
mutant). Individual points represent single CpGs (x axis, mean methylation beta value for all WT samples; y axis, mean methylation beta value for all R882 mutant
samples). CpGs with equal mean methylation beta values between WT and R882 samples appear along the line y = x, indicated in yellow. CpGs hypomethylated
in R882 samples appear below the line y = x. CpGs that were differentially methylated between the two sample sets (FDR < 0.01 and absolute value of mean
methylation difference > 0.15) are indicated in red.
(B) Scatter plot comparing mean methylation beta values at individual CpGs across all NK-AML cases categorized by DNMT3Amutation status (WT versus non-
R882 mutant). Individual points represent single CpGs (x axis, mean methylation beta value for all WT samples; y axis, mean methylation beta value for all non-
R882mutant samples). CpGs with equal meanmethylation beta values betweenWT and non-R882 samples appear along the line y = x, indicated in yellow. CpGs
(legend continued on next page)
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Dominant-Negative R882H DNMT3A in AMLthis NK-AML cohort, the R882 mutant alleles consisted of both
R882H (15/20) and R882C (5/20). We confirmed that the hypo-
methylation phenotype was nearly identical for the R882H and
R882C mutant samples (no CpGs were found to be significantly
differentially methylated between R882H and R882C samples by
supervised analysis, and no significant differences between
R882H and R882C samples were found when comparing mean
methylation values across the entire genome or within subsets
of CpGs based on their relation to gene loci or CGIs; Figures
S3C and S3D). This suggests that the dominant-negative activity
of the R882H mutation in DNMT3A can likely be extrapolated to
other R882mutations. Together, these findings demonstrate that
NK-AML genomes with DNMT3Amutations specifically at R882
exhibit focal hypomethylation at specific CpG residues, which
are found throughout the genome (Figure S3E). Discrete, large-
scale regional changes in methylation (Berman et al., 2012) are
not observed in these samples, however (Figures S3F and S3G).
We also assessed the relationship between gene expression
and DNA methylation in the 74 NK-AML cases with both RNA-
seq and 450K methylation array data. All samples exhibited
canonical relationships between levels of DNA methylation and
gene expression—increased promoter, CGI, and CpG island
shore methylation was associated with significantly decreased
gene expression, whereas increased gene body methylation
was associated with increased gene expression (Figures S4A
and S4B). However, hypomethylated CpGs in R882mutant sam-
ples identified by the supervised differential methylation analysis
were associated with variable expression changes (Figures 4A
and S4C). Genes associated with significantly hypomethylated
promoter or shore CpGs in R882 samples were statistically over-
represented among upregulated genes (>2-fold mean change)
relative to the overall gene expression changes between WT
and R882 mutant samples (p < 0.001 for both promoter and
shore CpGs, by chi-square test with Yates correction). In
contrast, genes associated with hypomethylated gene bodies
or CGI CpGs showed no enrichment in either upregulated or
downregulated genes (Figure S4C).
We next conducted a supervised differential gene expression
analysis (Anders and Huber, 2010), which identified only 228
differentially expressed genes between WT and R882 mutant
NK-AMLs (52 upregulated and 176 downregulated in the R882
samples; Benjamini-Holm adjusted p value < 0.05 and absolute
log2 fold change > 1; Tables S3 and S4; Figure S4D). Hierarchical
clustering of all NK-AML samples using only these 228 differen-
tially expressed genes revealed a high degree of intragenotype
variance (Figures S4D), reiterated by the failure of the first two
principal components based on gene expression to significantly
distinguish R882mutant fromWTNK-AML samples (Figure S4E).
This is in contrast to the extent to which the first two principal
components based on global DNA methylation successfullyhypomethylated in non-R882 samples appear below the line y = x. CpGs that w
absolute value of mean methylation difference > 0.15) are indicated in red.
(C) Mean methylation beta values are shown for each patient (categorized b
(by supervised analysis between WT and R882 mutant samples). p values were
(D) Mean methylation beta values are shown for each patient (categorized by DN
CGIs) of the 29,660 differentially methylated CpGs (by supervised analysis betwee
for multiple testing.
See also Figure S3 and Table S2.distinguish the majority of WT and R882 mutant samples (Fig-
ure S4F), emphasizing the greater similarity of R882 mutant
NK-AML samples by DNA methylation than by gene expression
patterns. The 52 genes that were significantly upregulated in
R882 mutant samples exhibited the predicted canonical hypo-
methylation of their promoters, CGIs, and CpG island shores
(Figure 4B). However, the 176 genes that were significantly
downregulated in R882 mutant samples were also hypomethy-
lated compared with WT samples (Figure 4B)—these genes
may be regulated by mechanisms other than DNA methylation.
Overall, these findings highlight the uniformity of the hypomethy-
lation signature found in R882 mutant samples but illustrate the
lack of a universal correlation between changes in the methyl-
ation state of individual CpGs and corresponding changes in
the expression of linked genes. Clearly, further studies will be
needed to better understand these findings.
Structural and Functional Consequences of the R882H
Mutation in DNMT3A
Several previous studies have demonstrated that the R882Hmu-
tation reduces (but does not eliminate) the de novo DNA methyl-
transferase activity of DNMT3A in vitro (Yamashita et al., 2010;
Yan et al., 2011; Holz-Schietinger et al., 2012). However, it is
not yet clear why mutations at R882 are over-represented
among the spectrum of DNMT3A mutations if their major effect
is a simple reduction in methyltransferase activity. We therefore
explored the possibility that R882 mutations may also possess
novel gain-of-function activities, such as altered cellular localiza-
tion and/or modified CpG substrate specificity.
To determine whether R882 mutations cause improper sub-
cellular targeting of DNMT3A, we expressed FLAG-tagged WT
and R882H DNMT3A (as well as GFP for a transfection and cyto-
plasmic-distribution control) in HEK293T cells and used immu-
nofluorescence to assess subcellular localization. This revealed
appropriate nuclear localization of bothWT and R882HDNMT3A
(Figure 5A). To verify this finding in primary NK-AML cells, we
performed nuclear-cytoplasmic separations after hypotonic lysis
of the leukemic cells, followed by Western blotting for DNMT3A
(because the abundance of this protein is too low to be detected
by immunofluorescence). Because WT and R882H DNMT3A
protein is present in equal abundance in primary AML cells (Fig-
ure 1C), cytoplasmic mislocalization of mutant DNMT3A protein
should be easily detected by this method. All measurable
DNMT3A protein was in the nuclear fraction regardless of the
R882 mutation status (Figure 5B).
To further evaluate the consequences of the R882H mutation
on DNMT3A functions, we purified full-length, human WT and
R882H DNMT3A using a mammalian tissue culture system (Fig-
ures S5A–S5C). We first used the recombinant proteins to
confirm that the R882H mutation reduces the de novoere differentially methylated between the two sample sets (FDR < 0.01 and
y DNMT3A mutation status) for the 29,660 differentially methylated CpGs
calculated by t tests corrected for multiple testing.
MT3A mutation status) for subsets (based on CpG relationship to gene loci or
nWT and R882 mutant samples). p values were calculated by t tests corrected
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Figure 4. Effects of DNMT3A Mutations on the Relationship between DNA Methylation and Gene Expression in NK-AML
(A) Variable expression changes are observed in genes associated with differentially methylated promoter or shore CpGs in R882 mutant DNMT3A NK-AML
samples. Each data point in the starburst plots represents themean DNAmethylation (x axis) andmean gene expression (y axis, log2 fold change) difference at an
(legend continued on next page)
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Figure 5. Cellular Localization and Function
of R882H DNMT3A Protein
(A) Immunofluorescence imaging of FLAG-tagged
WT and R882H DNMT3A. Note that WT and R882H
DNMT3Aproteinshave thesamenucleardistribution.
Left panels show GFP transfection control (green)
and anti-FLAG (red). Right panels show DAPI (blue)
and anti-FLAG (red). The scale bar indicates 10 mm.
(B)Nuclear/cytoplasmic fractionationof primaryNK-
AML cells (WT/WT and WT/R882H for DNMT3A) to
assess DNMT3A nuclear localization. The top panel
shows Western blot with anti-DNMT3A antibody.
The bottom panel shows Western blot with anti-
histone-H3 (nuclear, Nucl.) and anti-actin (cyto-
plasmic, Cyto.) antibodies. Lanes were loaded with
identical cell equivalents of lysate volumes.
(C) In vitro methylation of a linearized plasmid DNA
substrate (pcDNA3.1) by recombinant full-length
human WT DNMT3A or R882H DNMT3A: dose-
response assay with 6 hr incubation, and time-
course assay using 1 mg of total protein per reaction
(250 nM). Data are means ± SEM of three inde-
pendent experiments, each performed in triplicate.
(D) Logos of motifs demonstrating preferentially
methylated CpG sequences of WT and R882H
DNMT3A based on bisulfite sequencing of in vitro
methylated DNA templates.
See also Figure S5.
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Dominant-Negative R882H DNMT3A in AMLmethylation activity of DNMT3A. We measured the transfer of
tritiated methyl groups from [3H]SAM to substrate DNA (linear-
ized DNA from the pcDNA3.1 plasmid, which contains 334
CpG residues) and found that R882H DNMT3A had only 21.7%
(± SD of 4.4%) of the methyltransferase activity of WT DNMT3A
(Figure 5C).
Previous work demonstrated that DNMT3A has a preference
for specific DNA sequences flanking target CpGs (Wienholzindividual CpG comparing WT and R882 mutant DNMT3A samples. Data points in red are CpGs exhibitin
analysis between WT and R882 mutant samples) and also >2-fold changes in expression of their associa
pomethylated promoter or shore CpGs were statistically enriched for upregulated genes relative to the over
mutant samples (p < 0.001 for both promoter and shore CpGs by chi-square test with Yates correction; conti
and CGI CpGs are shown in Figure S4C.
(B) Differentially expressed genes in R882 mutant NK-AML consistently exhibit hypomethylation. Box-and-w
by mean methylation levels of individual promoter, gene body, CGI, or shore CpGs associated with either s
genes (n = 52) in R882 mutant NK-AML. *p < 0.05; **p < 0.005; *** p < 0.0005 by Wilcoxon signed-rank
upregulated and downregulated differentially expressed genes are hypomethylated in R882 mutant sampl
See also Figure S4 and Tables S3 and S4.
Cancer Cell 25, 442–et al., 2010). To assess whether the
R882H mutation alters the CpG-flanking
sequence preference, we performed
in vitro methylation on linearized
pcDNA3.1 plasmid DNA with recombinant
WT or R882H DNMT3A. We then per-
formed bisulfite sequencing of the methyl-
ated plasmid DNA from these reactions,
with 13 amplicons covering 114 CpGs.
Lists of 10 to +10 sequence contexts of
all target CpGs were generated from the
bisulfite sequencing results of these
in vitro methylation reactions. Sequenceswere then assigned weights corresponding to their measured
methylation beta values, and these weighted sequence motifs
were used to quantify preferential enrichment of bases upstream
or downstream of target CpGs using WebLogo (Crooks et al.,
2004). These data revealed identical CpG-flanking sequence
preferences for WT and R882H DNMT3A (Figure 5D; Spearman
correlation of rank ordered CpGs by methylation beta value be-
tween WT DNMT3A and R882H DNMT3A = 0.99), consistentg significant differential methylation (by supervised
ted genes. Genes associated with significantly hy-
all gene expression changes between WT and R882
ngency table, quadrants I/III versus II/IV). Gene body
hisker plots compare R882 mutant andWT samples
ignificantly downregulated (n = 176) or upregulated
test corrected for multiple testing. Note that both
es.
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Dominant-Negative R882H DNMT3A in AMLwith the expected TNCGCY motif previously described (Wien-
holz et al., 2010). Interestingly, the differentially methylated
CpGs found in our primary AML cohort (Figure 3A; Table S2)
were not enriched for the intrinsic DNMT3A 2 to +2 flanking
sequence preference.
R882H DNMT3A Exhibits Dominant-Negative Inhibition
of WT DNMT3A Activity
To determine whether recombinant R882H DNMT3A can inhibit
the activity of the WT enzyme, we measured the methylation
activity of increasing amounts of R882H DNMT3A mixed with a
fixed amount of WT DNMT3A protein. Surprisingly, we observed
a linear increase in the net enzymatic activity, reflecting the
summed activity of the two forms of DNMT3A in these 4 hr
in vitro reactions (Figure 6A). Therefore, using this assay, no
dominant-negative activity of the R882H mutant protein was
detected.
However, we suspected that in vitro mixing of WT and R882H
DNMT3A proteins might not recapitulate their interactions in
primary AML cells, where both proteins would be produced
and folded in the same compartment at the same time. We
therefore cotransfected HEK293T cells with equal amounts
of 63His-WT and 63His-R882H DNMT3A expression vectors
and then copurified both proteins (Figure 6B). In contrast to
the in vitro mixing experiment, the coexpressed, copurified,
in vivo mixed WT and R882H DNMT3A proteins displayed
a >80% reduction in methyltransferase activity relative to WT
DNMT3A (Figure 6C). To further test whether this represented
a dominant-negative activity of the R882H protein, we mea-
sured the relative abundance of both WT and R882H proteins
in each of our in vivo mixed samples generated by coexpres-
sion/copurification. We used a triple stage quadrupole (TSQ)
mass spectrometric approach that exploited the altered tryptic
cleavage site in DNMT3A produced by the R882H mutation, as
described above. This revealed similar amounts of each protein
in the copurified enzyme preparations, with WT:R882H ratios
ranging from 0.79 to 1.60 in four separate purifications
(mean = 1.05; Figure 6D). The R882H mutant protein therefore
must act in a dominant fashion to inhibit the methyltransferase
function of the WT protein, but only when the two proteins are
coproduced in the same cell.
Given the location of the R882H mutation in one of the self-
interacting domains of DNMT3A (specifically the ‘RD interface’;
Jurkowska et al., 2011) and the knowledge that the catalytic
domain of WT DNMT3A preferentially forms tetramers, we
postulated that the dominant-negative effect of R882H may be
due to an altered and/or disrupted oligomerization potential of
DNMT3A when WT and R882H proteins form complexes. Using
a Superose 6 size-exclusion column, we identified two popula-
tions of full-length WT DNMT3A oligomers: a macro-oligomer
peak with a mean molecular weight of 800 kDa (i.e., eight or
more DNMT3Amolecules) and a tetramer peak of DNMT3Amol-
ecules with a mean molecular weight of 450 kDa (Figure 7A). A
significant deficit in the tetramer complex was observed for
R882H DNMT3A, and a second, minor peak at a later elution
time (consistent with dimers) was also detected. In vivo mixed
(copurified) WT and R882H DNMT3A complexes exhibited a
pattern of oligomerization identical to R882H DNMT3A alone.
In contrast, in vitro mixed WT and R882H DNMT3A exhibited a450 Cancer Cell 25, 442–454, April 14, 2014 ª2014 Elsevier Inc.distribution of oligomers corresponding to the expected average
of theWT andR882H curves (Figure 7A). All species (WT, R882H,
as well as in vivo and in vitro mixed WT and R882H DNMT3A)
were able to form macro-oligomers. Previous studies, however,
have suggested that tetramers of the catalytic domain represent
the most active form of the methyltransferase (Kareta et al.,
2006; Jia et al., 2007; Holz-Schietinger et al., 2011).
To assess the relative methyltransferase activity of the
different oligomeric complexes, we used Superose 6 fractions
ofWTDNMT3A in in vitromethylation assays that were assessed
by pyrosequencing (Figure 7B). Of the eight fractions with
detectable levels of methyltransferase activity, the three most
active fractions were found in the tetramer elution peak. In
contrast, the three DNMT3A fractions associated with the
macro-oligomer peak contained only 53% of the total methyl-
transferase activity of the three tetramer-associated DNMT3A
fractions. We additionally verified the absence of catalytic activ-
ity from the corresponding tetramer fraction for R882H DNMT3A
(Figure 7B). Together, these findings provide further evidence
that the homotetramer is the most active multimeric species of
WT DNMT3A and suggest that the R882H protein must interact
with the WT protein intracellularly to form stable heterodimers
that are virtually inactive and that inhibit the formation of the
active WT homotetramers.
DISCUSSION
In this study, we explored the consequences of the R882H mu-
tation on DNMT3A function and identified the mechanism of its
dominant-negative effect on WT DNMT3A in mammalian cells.
Further, we identified a focal hypomethylation phenotype in
NK-AML cases possessing heterozygous DNMT3A mutations
at R882, which demonstrates the profound loss of de novo
methyltransferase activity resulting from the dominant-negative
consequences of these heterozygous alterations.
We and others have shown that recombinant DNMT3A with
the R882Hmutation has a reduced de novo DNAmethyltransfer-
ase activity (20% of WT levels), which therefore would predict
only a 40% reduction of the total de novo DNA methyltransfer-
ase activity of an AML cell with a heterozygousmutation—unless
the mutant protein acts as a dominant negative against the WT
protein. Surprisingly, mixing of purified recombinant WT and
R882H DNMT3A demonstrated additive methylation capacity
in an in vitro methylation assay, reflecting the summed activities
of the two enzymes. This suggests that WT and R882H DNMT3A
do not functionally interact with each other when purified sepa-
rately and mixed in solution.
DNMT3A possesses two protein-protein interacting faces
within the C-terminal catalytic domain. One is a hydrophobic
‘‘FF interface,’’ which mediates both homo-oligomerization and
the DNMT3A-DNMT3L interaction via stacking of four phenylala-
nine residues (two from each subunit). The other is a polar RD
interface for DNMT3A-DNMT3A self-interaction, which occurs
through a hydrogen-bonding network between arginine and
aspartate residues (Jurkowska et al., 2011). This RD interface, in
which the R882H mutation is found, forms the DNA binding site,
whereas both interfaces are essential for cofactor SAM binding
and overall catalytic activity of the enzyme (Holz-Schietinger
et al., 2011). In vitro, DNMT3A-DNMT3A self-interactions are
AC D
B
Figure 6. Dominant-Negative Effects of Recombinant R882H DNMT3A Protein Are Found Only after In Vivo Mixing
(A) In vitro methylation assay of linearized pcDNA3.1 using recombinant full-length human WT, R882H, or in vitro mixed WT and R882H DNMT3A.
(B) Schematic of cotransfection/copurification of WT and R882H DNMT3A for structure/function analysis and TSQmass spectrometry quantification of DNMT3A
proteins.
(C) In vitro methylation assay of linearized pcDNA3.1 usingWT, R882H, in vitro mixedWT, and R882HDNMT3A versus cotransfected/copurified in vivomixedWT
and R882H DNMT3A. Data are means ± SEM of four independent experiments, each performed in triplicate.
(D) Example of WT:R882H DNMT3A ratio quantification by TSQ mass spectrometry in in vivo mixed samples. Open circles, WT DNMT3A standards; red closed
circles, R882H DNMT3A standards; blue triangle, WT DNMT3A peptide from copurified WT+R882H sample; green diamond, R882H DNMT3A peptide from
copurified WT+R882H sample.
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(Purdy et al., 2010), suggesting that these complexes may have
a very slow dissociation rate.
We suspected that in vitro mixing of WT and R882H DNMT3A
might not recapitulate the DNMT3A complexes that would form
within a NK-AML cell that express bothWT andR882HDNMT3A.In vitro mixing may simply combine two pools of highly stable
DNMT3A multimers (one exclusively WT, the other exclusively
R882H) that do not form mixed multimers of WT and R882H
enzymes during incubations lasting several hours. We therefore
performed an in vivo mixing experiment by cotransfecting and
then copurifying WT and R882H DNMT3A from the sameCancer Cell 25, 442–454, April 14, 2014 ª2014 Elsevier Inc. 451
AB
Figure 7. R882H DNMT3A Fails to Form Homotetramers and Blocks
WT Homotetramer Formation in a Dominant-Negative Fashion
(A) Size-exclusion chromatography tracings of DNMT3A complexes (black,
WT; red, R882H; blue, cotransfected/copurified in vivo mixed WT and R882H;
green, in vitro WT and R882H DNMT3A). The x axis reflects the Superose 6
column elution time (run at 0.5ml/min; 20min =800 kDa estimatedmolecular
weight, 30 min = 450 kDa estimated molecular weight). The y axis reflects
arbitrary units of UV280 nm absorption of column eluates.
(B) Methyltransferase activity of WT DNMT3A or R882H DNMT3A complexes
(purified with size-exclusion chromatography) assessed by bisulfite py-
rosequencing of column fractions after in vitro methylation reactions. The
x axis reflects Superose 6 column elution time (run at 0.5 ml/min;
20 min =800 kDa estimatedmolecular weight, 30 min =450 kDa estimated
molecular weight). The y axis reflects relative methyltransferase activity,
calculated as the sum of methylation beta values across all 14 CpGs within the
pyrosequencing amplicon. The data are means ± SEM of three independent
experiments.
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possess WT and R882H DNMT3A in equal abundance by
mass spectrometry) indeed demonstrated that the R882H
mutant form of DNMT3A possesses a potent dominant-negative
activity, essentially eliminating the methyltransferase activity of
the WT enzyme. Size-exclusion chromatography analysis
demonstrated that the mutant enzyme inhibits the ability of the
WT enzyme to form functional tetramers. Earlier work suggests
that tetrameric WT DNMT3A catalytic domains formed the
most active methyltransferase (Kareta et al., 2006; Purdy et al.,
2010; Jurkowska et al., 2011); we have shown here that tetra-
mers of full-length WT DNMT3A protein are required for maximal
de novo methyltransferase activity. Together, these findings
define the mechanism through which R882H DNMT3A is able
to function as a dominant-negative inhibitor of de novo DNA
methylation.
We also examined the 85 NK-AML cases from the TCGA AML
cohort (Ley et al., 2013), identifying a small (but statistically sig-
nificant) overall reduction in CpG methylation in the genomes of
AML cases with DNMT3A mutations at R882, which was not
found in cases with non-R882 mutations. Many common can-
cer-associated DNA methylation phenotypes involve changes
at specific functional or structural elements of the genome,
such as the CpG-island methylator phenotype in glioblastoma
(Noushmehr et al., 2010) and the long-range hypomethylation452 Cancer Cell 25, 442–454, April 14, 2014 ª2014 Elsevier Inc.of nuclear lamina-associated domains in colon cancer (Berman
et al., 2012). In contrast, the focal hypomethylation associated
with R882 mutations occurred at specific CpGs throughout the
genome, instead of in specific blocks.
The hypomethylated loci in R882 mutant NK-AML samples
were enriched for CpG island shores, which others have shown
to be regions of enrichment for tissue-specific differential
methylation (Irizarry et al., 2009). Nonetheless, the profound
R882 mutant hypomethylation phenotype entailed significant
reductions in methylation in all subsets of CpGs based on their
relationships to annotated genetic loci (promoter, gene body,
30 UTR, or intergenic) or CGIs (CpG island, shore, shelf, or
open sea). Both WT and R882 mutant cases exhibited canonical
relationships between global levels of DNAmethylation and gene
expression; however, significantly hypomethylated CpGs in
R882 mutant samples were associated with variable changes
in the expression of linked genes. Although many of the affected
genes have been shown to play important roles in AML, addi-
tional studies will be required to fully understand how these
changes in gene expression may contribute to leukemogenesis.
In sum, we have elucidated the protein-intrinsic mechanism
that explains the dominant-negative potential of the R882H alter-
ation in DNMT3A and have demonstrated that mutations at this
residue contribute to a focal hypomethylation phenotype in NK-
AML samples. These genetic and molecular data suggest that
there are two distinct classes of DNMT3A mutations that
contribute to leukemogenesis in different ways. The first entails
the dominant-negative R882 mutations, which are expected to
cause a near complete loss of de novomethyltransferase activity
in an affected AML cell, whichmay directly cause the focal hypo-
methylation phenotype. The second class includes the other
40% of DNMT3A mutations, which are equally distributed
between frameshift/nonsense/splice-site mutations and other
missense alleles (the most common of which, S714C, has only
been reported in 11 samples to date, compared with >1000
R882 mutations; Forbes et al., 2011). Many cases with non-
R882 mutations are predicted to cause haploinsufficiency for
DNMT3A (e.g., deletions, frameshifts, splice-site, and nonsense
mutations); these cases do not exhibit significant changes in
DNA methylation. Additional missense mutations in DNMT3A
that are not at positionR882maycontribute toAMLpathogenesis
by alternative mechanisms that do not directly involve altered de
novo methyltransferase activity or DNA methylation patterns.
Because DNMT3A interacts with many other proteins, one or
more alternative mechanisms may be relevant for AML associ-
ated with the wide variety of mutations that are non-R882.
Regardless, these data suggest that R882 and non-R882
DNMT3A mutations in AML patients may in fact be different en-
tities that will ultimately require different therapeutic approaches.
EXPERIMENTAL PROCEDURES
Mass Spectrometry, Immunofluorescence, Western Blot, Cell
Culture, Bisulfite Pyrosequencing, Bisulfite Sequencing, and
Oligonucleotide Sequences
These procedures are described in Supplemental Experimental Procedures.
Primary AML Samples
All cryopreserved primary AML samples were collected as part of a study
approved by the Human Research Protection Office at Washington University
Cancer Cell
Dominant-Negative R882H DNMT3A in AMLSchool of Medicine after patients provided informed consent in accordance
with the Declaration of Helsinki.
DNA Methylation and RNA-seq Analysis
Illumina Infinium HumanMethylation450 BeadChip and RNA-seq data from
NK-AML patients (and normal human control samples derived from purified
cells from bone marrow) were obtained from the TCGA-AML data set (Ley
et al., 2013). All DNAmethylation and RNA-seq analyses were performed using
the ‘‘R’’ software environment. The methylation data were normalized for
background correction using the BioConductor MethyLumi package. Probes
were removed from the data set that were nonunique, within 10 bases of a
single-nucleotide polymorphism found in dbSNP, and/or on the X or Y chromo-
somes (yielding 464,198 probes for downstream analysis). Supervised
differential methylation analysis was performed using CpGassoc with logit-
transformed methylation beta values. Gene and CGI annotations were based
on annotation provided by Illumina. For the purposes of this study, CpGs from
the four categories TSS1500, TSS200, 50 UTR, and first exon were grouped
into one ‘‘promoter’’ annotation. Hierarchical clustering analysis was per-
formed with the heatmap.2 function (gplots package) using the 5,000 CpGs
with the greatest SD across all NK-AML samples. Supervised differential
expression analysis was performed using DESeq2.
Statistical Analysis
Statistical analyses were performed using chi-square tests for categorical vari-
ables and t tests for continuous variables. All reported significance metrics are
corrected for multiple testing by Benjamini-Holm (FDR) or Bonferonni methods
(p values) unless otherwise noted.
Protein Purification
N-terminal 63His tags and C-terminal FLAG tags were cloned into a full-length
DNMT3A (NM_175629.1) expression vector using the pCMV6 (Origene) back-
bone. Five million HEK293T cells were plated per 15 cm plate and transfected
after 24 hr by standard calcium-phosphate transfection protocols with 25 mg of
WT, 25 mg of R882H, or 12.5:12.5 mg of WT:R882H 63His-DNMT3A-FLAG
expression vectors. Twenty-four hours after transfection, the media on the
cells were replaced, and at 48 hr, the cells were harvested in PBS by trituration.
The cells were then centrifuged and resuspended at five million cells/ml in
20mMsodium phosphate, 250mMNaCl, 30mM imidazole (pH 7.4) plus a pro-
tease inhibitor cocktail (Sigma P8465). Cells were lysed by repeated (more
than three times) snap-freezing, and thawing, and then the lysates were clar-
ified by centrifugation at 10,0003 g for 20 min. The supernatants were filtered
through aWhatman 25mmGD/X PES 0.45 mmpore filter and then loaded onto
a 2 ml GE HisTrap HP column and washed with 20 ml of 20 mM sodium phos-
phate, 500 mM NaCl, 30 mM imidazole (pH 7.4). The protein was eluted in
20 mM sodium phosphate, 250 mM NaCl, 400 mM imidazole (pH 7.4) and
then dialyzed into 25 mM Tris-HCl, 150 mM NaCl, 0.5 mM dithiothreitol
(DTT), 0.5 mM EDTA (pH 7.2; with 5% v/v glycerol for making 80C
frozen stocks). Protein concentrations were determined by Pierce BCA Kit
(ThermoScientific), and then purity was confirmed using the Pierce Silver Stain
Kit (ThermoScientific).
In Vitro Methylation
In vitro methylation reactions were performed on linearized pcDNA3.1 (Invi-
trogen) or linearized pcDNA3.1 containing a 144 bp fragment of the GSTP1
promoter (see Supplemental Experimental Procedures) cloned into the EcoRI
restriction digest site. Reactions were carried out at 37C in a buffer of
20 mM HEPES, 30 mM NaCl, 0.5 mM DTT, 1 mM EDTA (pH 7.2), plus
0.2 mg/ml BSA and 5 mM 3H-labeled SAM (PerkinElmer). Reactions were
quenched by 100-fold dilution in ice-cold 10% trichloroacetic acid (TCA)
with 35 mg of tRNA carrier (Sigma). Samples were spotted onto Whatman
GF/C 25 mm filters and washed with 5 ml of ice-cold 10% TCA twice and
then 5 ml of 95% ethanol once, dried, and measured by a scintillation
counter.
Size-Exclusion Chromatography
Purified DNMT3A proteins (100 ml of 0.5 mg/ml protein) were loaded onto a
Superose 6 HR 10/30 column controlled by an AKTApurifier with UNICORN
software (GE v5.11). The flow rate was kept constant at 0.5 ml/min using arunning buffer of 25 mM Tris-HCl, 150 mM NaCl, 0.5 mM DTT, 0.5 mM
EDTA (pH 7.2). To generate a standard molecular weight curve, 100 mg of
each of five proteins were used (urease, BSA, chicken egg albumin, carbonic
anhydrase, and a-lactalbumin; Sigma MWND500). The molecular weights of
DNMT3A complexes were calculated by nonlinear regression based on Kav
values determined from elution values, the column void volume, and the total
column volume (GraphPad Prism 6.0).
SUPPLEMENTAL INFORMATION
Supplemental information includes Supplemental Experimental Procedures,
five figures, and four tables and can be found with this article online at
http://dx.doi.org/10.1016/j.ccr.2014.02.010.
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